Early versus late response to PD-1-based immunotherapy in metastatic melanomaGeorg Lodde, Selma Ugurel, Jochen Utikal et al.|European Journal of Cancer|2024Cited by 9
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomasPhilipp Jansen, Klaus Griewank, Wolfgang Galetzka et al.|European Journal of Cancer|2024Cited by 4